Erasca Finalizes $225M Public Offering at $10.00/Share
summarizeSummary
Erasca has finalized the terms of its public offering, initially announced on January 20, 2026. The offering consists of 22.5 million shares at $10.00 per share, raising $225 million before deductions. This capital raise strengthens Erasca's balance sheet, providing resources for ongoing research and development.
check_boxKey Events
-
Public Offering Priced
Erasca priced its public offering of 22.5 million shares at $10.00 per share, raising $225 million in gross proceeds.
-
Underwriting Agreement
The company entered into an underwriting agreement with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC, and Evercore Group L.L.C.
-
Use of Proceeds
Erasca intends to use the net proceeds to fund research and development, working capital, and other general corporate purposes.
auto_awesomeAnalysis
Erasca has finalized the terms of its public offering, initially announced on January 20, 2026. The offering consists of 22.5 million shares at $10.00 per share, raising $225 million before deductions. This capital raise strengthens Erasca's balance sheet, providing resources for ongoing research and development.
在该文件披露时，ERAS的交易价格为$10.30，交易所为NASDAQ，所属行业为Life Sciences，市值约为$29.2亿。 52周交易区间为$1.01至$10.67。 这份文件被评估为中性市场情绪，重要性评分为8/10。